Optimizing VIM Targeting for Radiosurgery in Severe Tremor

Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Nov 18, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new method for targeting a specific part of the brain called the ventro-intermediate nucleus of the thalamus (VIM) to treat severe essential tremor, a condition that causes uncontrollable shaking and can significantly impact daily life. The trial will compare the traditional way of locating this area for treatment with a new algorithm developed by a research team, called the VIM-RS-LAT-1.0. The goal is to see if the new method is just as effective as the standard approach.

To participate in this study, individuals must be between 18 and 85 years old and have severe tremor that has not responded to medication. They will need to have a brain MRI that shows no abnormalities and must be able to provide informed consent. Participants can expect to be randomly assigned to one of two groups, where one group will receive the traditional treatment and the other will receive the new targeting method. The trial is not yet recruiting, but it aims to better understand how to improve treatment options for those suffering from severe tremors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Advanced, disabling, drug-resistant essential tremor
• • Patient selected as part of the multidisciplinary concertation meeting on abnormal movements
• • Patient aged 18 to 85
• • Brain MRI showing no anatomical abnormality contraindicating radiosurgical procedure
• • MATTIS ≥ 130
• • Subject affiliated to or benefiting from a social security scheme
• • Free, informed and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research).
• Exclusion Criteria:
• • Patients with a contraindication to brain MRI (pacemaker, intracerebral metal object, etc.)
• • Pregnant or breast-feeding women